Industry

RICHARDSON, Texas–(BUSINESS WIRE)–#agenticai—MedeAnalytics, an industry pioneer in AI-powered enterprise healthcare intelligence, analytics, and data management, and Basys.ai, an innovation leader in agentic AI for healthcare, today announced a strategic partnership designed to accelerate decision-making, reduce cost, and improve utilization management performance for all payer lines of business. MedeAnalytics brings its broad, established healthcare footprint and … [Read more…]

SYDNEY–(BUSINESS WIRE)–Box, Inc. (NYSE: BOX), the leading Intelligent Content Management (ICM) platform, today announced that the Heart Research Institute (HRI), a renowned medical research institute, selected Box to centralise and secure its research content. HRI will leverage Box to gain AI-power insights across content sources, seamlessly integrate into research applications, and maintain robust compliance features … [Read more…]

Award spotlights Dr. Mostashari’s success advancing value-based care nationwide BETHESDA, Md.–(BUSINESS WIRE)–Modern Healthcare has recognized Farzad Mostashari, MD, co-founder and CEO of Aledade, the nation’s largest network of independent value-based primary care, as one of the 100 Most Influential People in Healthcare of 2025. The publication praised Mostashari for his role in advancing value-based care … [Read more…]

Upcoming ISG Provider Lens® report will examine how providers enable digital, AI-driven transformation across the life sciences value chain STAMFORD, Conn.–(BUSINESS WIRE)–$III #CROs–Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining IT service providers and contract research organizations (CROs) across key digital and operational … [Read more…]

BOSTON–(BUSINESS WIRE)–PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across … [Read more…]

OXFORD, England–(BUSINESS WIRE)–#Nanopore–Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, today announces the appointment of Francis Van Parys as Chief Executive Officer (“CEO”). Francis will join the Company and the Board as an Executive Director on 2 March 2026. Francis brings more than 20 years of experience … [Read more…]

NEW YORK–(BUSINESS WIRE)–Hercules Pharmaceuticals (Hercules), a national leader in pharmaceutical distribution, today announced that it has been approved as an authorized distributor in the 340B Prime Vendor Program distribution network, administered by Apexus, HRSA’s designated prime vendor for the 340B Drug Pricing Program. Hercules joins the 340B Prime Vendor Program distribution network as an independent … [Read more…]

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne—BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on … [Read more…]

VIENNA–(BUSINESS WIRE)–#AOPHealth—AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights … [Read more…]

Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting … [Read more…]